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Abstract
Impairment of the protein C pathway plays a central role in the
pathogenesis of sepsis. Administration of recombinant human
activated protein C (rhAPC) may correct the dysregulated anti-
coagulant mechanism and prevent propagation of thrombin
generation and formation of microvascular thrombosis. Further-
more, it may simultaneously modulate the inflammatory response. It
is likely that the beneficial effect of rhAPC observed in experimental
and clinical studies of severe sepsis results from a combination of
mechanisms that modulate the entangled processes of coagulation
and inflammation. This review presents an analysis of the various
mechanisms of action of rhAPC in sepsis.
Introduction
In all patients with sepsis there is abundant activation of
inflammatory pathways, which results in demonstrable circula-
ting levels of inflammatory cytokines and chemokines, activa-
ted inflammatory cells and other markers of increased
inflammatory activity. Virtually all septic patients exhibit
coagulation abnormalities as well. These abnormalities range
from subtle activation of coagulation, which can only be
detected by sensitive markers of coagulation factor activa-
tion; to more marked activation, which may be detectable
based on a small decrease in platelet count and subclinical
prolongation of global clotting times; and finally to fulminant
disseminated intravascular coagulation (DIC), which is
characterized by simultaneous widespread microvascular
thrombosis and profuse bleeding from various sites [1].
Septic patients with severe forms of DIC may present with
thromboembolic disease or clinically less apparent micro-
vascular failure that predominantly presents as multiple organ
dysfunction [2,3]. Interestingly, there is a tight, bidirectional
relationship between activation of inflammation and coagu-
lation, in which inflammatory activity results in activation of
coagulation but activated coagulation proteases can also
affect inflammatory pathways [4].
Activated protein C (APC) appears to play a central role in
the pathogenesis of sepsis and associated organ dys-
function. There is ample evidence that insufficient functioning
of the protein C pathway contributes to the derangement of
coagulation observed in sepsis [5,6]. The protein C system is
summarized in Figure 1. The circulating zymogen protein C is
activated by the endothelial cell bound thrombomodulin once
this is activated by thrombin [7]. APC acts in concert with its
co-factor, protein S, and can proteolytically degrade the co-
factors Va and VIIIa, which are essential for coagulation; APC
is therefore an effective anticoagulant. The endothelial protein
C receptor (EPCR) not only accelerates activation of protein
C several fold but it also serves as a receptor for APC, and
binding of APC to EPCR may amplify its anticoagulant and
anti-inflammatory effects [8]. A recent study [9] demonstrated
that exposure of cultured endothelial cells to APC results in
release of microparticles that contain EPCR, but the
relevance of that observation to coagulation or inflammation
is not yet clear.
In patients with sepsis the APC system malfunctions at
virtually all levels. First, plasma levels of the zymogen protein
C are low or very low because of impaired synthesis,
consumption and degradation by proteolytic enzymes such
as neutrophil elastase [10-12]. Furthermore, significant
downregulation of thrombomodulin caused by pro-
inflammatory cytokines such as tumour necrosis factor-α and
interleukin-1 has been demonstrated, resulting in diminished
protein C activation [13,14]. Low levels of free protein S may
further compromise the functioning of the protein C system.
In plasma, 60% of the co-factor protein S is complexed to the
complement regulatory protein C4b-binding protein (C4bBP).
Increased plasma levels of C4bBP, which occur as a
consequence of the acute phase reaction in inflammatory
disease, may result in relative protein S deficiency, which
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further contributes to a procoagulant state during sepsis.
Although it has been shown that the β-chain of C4bBP
(which mainly governs binding to protein S) is not much
affected by the acute phase response [15], support for this
hypothesis comes from studies conducted in baboons [16] in
which infusion of C4bBP in combination with a sublethal
dose of Escherichia coli resulted in a lethal response, with
severe organ damage due to DIC. Finally (but importantly), in
sepsis EPCR has been shown to be downregulated, which
may further adversely affect the function of the protein C
system [17]. Apart from these effects, sepsis may induce
resistance to APC by other mechanisms that are partly
dependent on a sharp increase in factor VIII levels (released
from endothelial cells) and partly due to as yet unidentified
mechanisms [18].
Ability of rhAPC to correct the defective
protein C pathway and abnormal coagulation
in sepsis
Administration of APC in a baboon model of intravenous
E. coli administration resulted in survival of all animals,
whereas all control animals in the same experiment died [19].
A similar beneficial effect was observed in rabbits with
meningococcal endotoxin shock. In a rat model of septic
shock, administration of APC prevented tumour necrosis
factor-α mediated hypotension, probably caused by modula-
tion of the nitric oxide response [20]. In patients with severe
sepsis, administration of recombinant human activated
protein C (rhAPC) resulted in remarkable improvement in
microcirculatory perfusion [21]. Conversely, experiments
conducted in baboons in which the protein C pathway was
blocked with monoclonal antibodies resulted in complete
lethality in an otherwise sublethal model of bacteraemia. In
this same model, blockade of the EPCR also resulted in a
more severe response to sublethal E. coli bacteraemia [17].
In addition to these observations in experimental sepsis
models, APC was shown to have antithrombotic properties in
experimental thrombosis models in dogs, rabbits and
baboons [22,23]. Interestingly, APC may also affect fibrino-
lysis by inhibiting plasminogen activator inhibitor type 1 (a
fibrinolytic inhibitor). In a rat model of DIC, APC was shown
to block activity of plasminogen activator inhibitor type 1, and
other experiments demonstrated the ability of APC to
enhance clot lysis in vivo [24].
More definitive proof of the beneficial effect of rhAPC in
severe sepsis comes from clinical studies [25,26]. These
studies are reviewed in detail in other reviews included in this
supplement [27-29] and are not discussed in detail here.
However, it may be of interest to review the evidence that
rhAPC acts as an anticoagulant agent in these studies.
First, it should be noted that the selected dose of rhAPC was
based on the effect on D-dimer levels in a phase II clinical trial
Figure 1
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[25]. Indeed, in the pivotal PROWESS (Recombinant Human
Activated Protein C Worldwide Evaluation in Severe Sepsis)
trial [26], septic patients who were treated with APC
exhibited a significant decrease in D-dimer levels as
compared with placebo control individuals. D-dimer levels
dropped by 25% after 2 days of APC administration, which
was in contrast to a 10% increase in placebo-treated
patients. In a more detailed analysis of coagulation activation
upon administration of rhAPC, it was clearly demonstrated
that markers of thrombin generation sharply dropped almost
immediately after initiation of the APC infusion [30]. Second,
subgroup analyses of trials including patients with severe
sepsis [31,32] demonstrated that patients with the most
extreme coagulation abnormalities benefit the most from
treatment with rhAPC. The relative risk reduction in mortality
among patients with sepsis and DIC who received APC was
38%, as compared with a relative risk reduction of 18%
observed among patients with sepsis who did not have DIC.
Interestingly, the dynamics of coagulation abnormalities in the
first days after intensive care unit admission for severe sepsis,
including the response of the protein C system, is a strong
predictor of outcome [33].
It is difficult to assess whether this anticoagulant effect of
rhAPC translates into an antithrombotic effect. In the recently
concluded XPRESS (Xigris [drotrecogin alfa] and Prophyl-
actic Heparin in Severe Sepsis) study [34], all patients with
severe sepsis received rhAPC but were also randomly
assigned to receive prophylactic heparin or placebo. The
main conclusion of this study was that heparin was not
equivalent to placebo and might have a beneficial effect on
28-day mortality. Of note, this advantageous effect of heparin
was completely due to a greater incidence of death and
thrombotic adverse events in the patients receiving heparin
but who were randomly assigned to placebo (in other words,
those who stopped heparin during the trial). There was a
markedly low incidence of venous thromboembolism in this
study compared with previous reports (the incidence did not
differ between placebo patients and patients receiving
heparin), even though all patients underwent screening
ultrasound for venous thrombosis at around day 6 of
admission. In addition, a report of small series of patients with
severe sepsis who were treated with rhAPC [35] demon-
strated a lack of thrombotic obstruction of haemofiltration
circuits, even in the absence of heparin or other anti-
coagulants.
Apart from the systemic response, there may be a differential
localized effect of rhAPC on coagulation. The localized effect
of APC appears to be particularly marked in the pulmonary
compartment. In experiments involving unilateral instillation of
endotoxin into healthy individuals, systemic administration of
rhAPC resulted in a marked reduction in bronchoalveolar
activation of coagulation [36]. This observation may be
relevant because the vast majority of patients with severe
sepsis in the various trials had a pulmonary source of
infection. An interesting novel finding is the modulatory
influence of alveolar epithelial cells on the protein C pathway
[37]. It is likely that the underlying mechanism involves
shedding of EPCR and thrombomodulin by metalloproteinases.
APC as an inflammatory mediator in sepsis
Evidence that APC acts as an important mediator in the
systemic inflammatory response in sepsis comes from experi-
ments showing that blocking the protein C pathway in septic
baboons exacerbated the inflammatory response [38]. In
contrast, administration of APC ameliorated the inflammatory
activation that occurred upon intravenous infusion of E. coli
[38]. Similar experiments in rodents yielded identical results
and demonstrated a beneficial effect on inflammatory effects
in various tissues [39]. Support for the notion that APC has
anti-inflammatory properties comes from in vitro findings,
demonstrating an APC-binding site on monocytes that may
mediate downstream inflammatory processes [40,41]. It also
received support from experiments showing that APC can
block nuclear factor-κB nuclear translocation, which is a
prerequisite for increased levels of pro-inflammatory cytokines
and adhesion molecules [42]. These in vitro findings are
supported by in vivo studies in mice with targeted disruption
of the protein C gene [43,44]. In these mice with genetic
deficiencies of protein C, endotoxaemia was associated with
more marked increases in pro-inflammatory cytokines and
other inflammatory responses than in wild-type mice.
It is likely that the effects of APC on inflammation are
mediated by EPCR, which may mediate downstream inflam-
matory processes [45]. Binding of APC to EPCR influences
gene expression profiles of cells by inhibiting endotoxin-
induced calcium fluxes in the cell and by blocking nuclear
factor-κB nuclear translocation [41,42]. The EPCR-APC
complex itself can translocate from the plasma membrane
into the cell nucleus, which may be another mechanism of
modulation of gene expression, although the relative contribu-
tions of this nuclear translocation and cell surface signalling are
unclear [5]. Some studies have also suggested that EPCR
binding of APC can result in activation of protease activated
receptor (PAR)-1 and thereby affect cytokine responses [46].
In contrast, other experiments demonstrated that a significant
physiological role for activation of PAR-1 by APC to be less
probable [47]. Like APC, EPCR itself may have anti-
inflammatory properties. Soluble EPCR (the extracellular
domain of the cell-associated EPCR shed from the cell
surface by the action of an inducible metalloproteinase [48])
can bind to proteinase 3, which is an elastase-like enzyme.
The resulting complex binds to the adhesion integrin macro-
phage 1 antigen (Mac-1) [49]. Of considerable interest is that
the crystal structure of EPCR is remarkably similar to the
structure of the MHC class 1/CD1 family of proteins, the
majority of which are involved in inflammation [50]. Blocking
the EPCR with a specific monoclonal antibody aggravated
both the coagulation and the inflammatory response to E. coli
infusion [17].
Available online http://ccforum.com/content/11/S5/S3Apart from the influence of APC on cytokine levels,
remarkable effects of the agent on leucocyte chemotaxis and
adhesion of circulating leucocytes to the activated endo-
thelium have been demonstrated [51,52]. This was confirmed
in a hamster endotoxaemia model at concentrations of rhAPC
that preclude a significant anticoagulant effect [53]. The
localized effect of APC in the lung has also been shown to
exhibit these anti-inflammatory properties [54]. APC was
shown to inhibit the expression of platelet-derived growth
factor in the lung [55], which may reflect a potential
mechanism underlying this localized effect. Also, APC was
shown to protect against disruption of the endothelial cell
barrier in sepsis, probably by interfering with EPCR and
PAR-1 on endothelial cells [56-58].
Finally, APC can inhibit endothelial cell apoptosis, which also
appears to be mediated by binding of APC to EPCR and to
require PAR-1 [46,59]. Signalling through this pathway can
affect Bcl-2 homologue protein, which can inhibit apoptosis,
and further suppresses p53, which is a pro-apoptotic
transcription factor [60,61].
Conclusion
Inadequate functioning of the protein C system, and in
particular APC, plays a central role in the pathogenesis of
sepsis. Attempting to restore the function of this pathway in
patients with sepsis appears to be a rational approach and is
supported by the beneficial effect of APC in experimental
models of sepsis and in clinical studies. Apart from its evident
effect on the coagulation system and the ability of rhAPC to
correct the deranged coagulation system in severe sepsis, a
series of pleiotropic modulating effects of APC on inflammatory
cytokines and cells as well as protective effects on disrupted
endothelium have been reported. It should be noted that many
of the effects on inflammatory cells and pathways, as well as
the cytoprotective effect, have mostly been demonstrated in
vitro and sometimes at inordinately high concentrations of
APC. The relevance of these findings to the human in vivo
situation and their importance to the treatment of sepsis remain
to be established. Although the relative importance of the
anticoagulant effect versus the inflammation-modulating effect
of rhAPC is not clear, it is tempting to hypothesize that a
combined effect is responsible for the benefit from rhAPC.
Indeed, strategies aimed at restoring physiological pathways
with less marked effects on inflammation (such as
administration of antithrombin or recombinant tissue factor
pathway inhibitor) were less successful. Further insight into the
various mechanisms of action of rhAPC on the entangled
processes of inflammation and coagulation may permit more
detailed dissection of the relative importance of the various
pathways that contribute to the pathogenesis of sepsis,
potentially culminating in improved treatment strategies.
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